



The Vacuolar Zinc Transporter TgZnT Protects *Toxoplasma gondii* from Zinc Toxicity

Nathan M. Chasen,^{a,b} Andrew J. Stasic,^{a,c} Beejan Asady,^{a,c} Isabelle Coppens,^d Silvia N. J. Moreno^{a,e}

^aCenter for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA

^bDepartment of Infectious Diseases, University of Georgia, Athens, Georgia, USA

^cDepartment of Microbiology, University of Georgia, Athens, Georgia, USA

^dDepartment of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA

^eDepartment of Cellular Biology, University of Georgia, Athens, Georgia, USA

ABSTRACT Zinc (Zn^{2+}) is the most abundant biological metal ion aside from iron and is an essential element in numerous biological systems, acting as a cofactor for a large number of enzymes and regulatory proteins. Zn^{2+} must be tightly regulated, as both the deficiency and overabundance of intracellular free Zn^{2+} are harmful to cells. Zn^{2+} transporters (ZnTs) play important functions in cells by reducing intracellular Zn^{2+} levels by transporting the ion out of the cytoplasm. We characterized a *Toxoplasma gondii* gene (TgGT1_251630, TgZnT), which is annotated as the only ZnT family Zn^{2+} transporter in *T. gondii*. TgZnT localizes to novel vesicles that fuse with the plant-like vacuole (PLV), an endosome-like organelle. Mutant parasites lacking TgZnT exhibit reduced viability in *in vitro* assays. This phenotype was exacerbated by increasing zinc concentrations in the extracellular media and was rescued by media with reduced zinc. Heterologous expression of TgZnT in a Zn^{2+} -sensitive *Saccharomyces cerevisiae* yeast strain partially restored growth in media with higher Zn^{2+} concentrations. These results suggest that TgZnT transports Zn^{2+} into the PLV and plays an important role in the Zn^{2+} tolerance of *T. gondii* extracellular tachyzoites.

IMPORTANCE *Toxoplasma gondii* is an intracellular pathogen of human and animals. *T. gondii* pathogenesis is associated with its lytic cycle, which involves invasion, replication, egress out of the host cell, and invasion of a new one. *T. gondii* must be able to tolerate abrupt changes in the composition of the surrounding milieu as it progresses through its lytic cycle. We report the characterization of a Zn^{2+} transporter of *T. gondii* (TgZnT) that is important for parasite growth. TgZnT restored Zn^{2+} tolerance in yeast mutants that were unable to grow in media with high concentrations of Zn^{2+} . We propose that TgZnT plays a role in Zn^{2+} homeostasis during the *T. gondii* lytic cycle.

KEYWORDS *Toxoplasma gondii*, zinc transport, transporters

Toxoplasma gondii is an apicomplexan parasite and is an important cause of congenital disease and infection in immunocompromised patients. The parasite can cause ocular uveitis in immunocompetent individuals (1), pneumonia or encephalitis in immune-deficient patients (2), and serious malformations in congenitally infected children (3). The pathogenesis of *T. gondii* is linked to its lytic cycle, which comprises secretion of adhesins from specific secretory organelles, invasion, intracellular replication, and egress. *T. gondii* replicates exclusively inside a host cell, where it resides inside a parasitophorous vacuole (PV) (4). The PV membrane allows the host cytosolic ions to equilibrate with the lumen of the vacuole, and upon exit, *Toxoplasma* is exposed to dramatic changes in its surrounding ionic and nutrient milieu. We previously characterized a lysosomal compartment, termed the plant-like vacuole (PLV) or VAC, and

Citation Chasen NM, Stasic AJ, Asady B, Coppens I, Moreno SNJ. 2019. The vacuolar zinc transporter TgZnT protects *Toxoplasma gondii* from zinc toxicity. *mSphere* 4:e00086-19. <https://doi.org/10.1128/mSphere.00086-19>.

Editor Ira J. Blader, University at Buffalo

Copyright © 2019 Chasen et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Silvia N. J. Moreno, smoreno@uga.edu.

Received 5 February 2019

Accepted 30 April 2019

Published 22 May 2019

proposed an important role for this organelle in controlling ionic stress during the short extracellular phase of the parasite (5, 6). The PLV becomes prominent when *Toxoplasma* is extracellular and its proton pumps (7, 8) create a proton gradient that is used for the countertransport of Ca^{2+} (5) and other ions.

The zinc ion (Zn^{2+}) must be tightly regulated because both a deficiency and an excess of cytoplasmic free Zn^{2+} are deleterious for cells (9–11). Zinc is an essential element that acts as a cofactor for a large number of enzymes and regulatory proteins and that also participates in cell signaling (12, 13). More than 300 enzymes that utilize Zn^{2+} have been identified across all enzyme classes and phyla (14). Notably, 3 to 10% of the genes encoded by the human genome, over 3,000 in total, are thought to encode proteins that interact with Zn^{2+} , a number that is likely underestimated because new Zn^{2+} -protein interactions are still being discovered (15–17).

Enzyme inhibition, disruption of protein folding, and induction of apoptosis are some of the proposed mechanisms by which high concentrations of Zn^{2+} may be deleterious to cells (9–11). The consistent abundance of Zn^{2+} in our environment during the evolution of life has introduced a selective pressure on all living organisms to evolve complex mechanisms to regulate total cellular Zn^{2+} and intracellular free Zn^{2+} . The total concentration of cellular zinc in eukaryotic cells typically ranges from 0.1 to 0.5 mM (18); however, most of the Zn^{2+} in cells is bound to proteins and sequestered into so-called zincosomes (19) or lysosomal compartments. The resting intracellular free Zn^{2+} concentration is reported to be at picomolar levels (20), and cytosolic zinc-binding proteins exhibit an affinity for Zn^{2+} in the picomolar range (21, 22). These picomolar concentrations represent less than 0.0001% of total cellular Zn^{2+} , exemplifying the precise control of cytoplasmic free Zn^{2+} in eukaryotic cells. Free Zn^{2+} in the extracellular space was reported to be in the range of 5 to 25 nM in the central nervous system (23), which is more than 1,000-fold higher than the predicted intracellular concentration.

T. gondii is exposed to sharp changes of extracellular Zn^{2+} upon egress, and we propose that the PLV plays an important role in the ability of *Toxoplasma* to efficiently survive these changes. In the present work, we characterized a ZnT family Zn^{2+} transporter (TgGT1_251630, TgZnT). We localized TgZnT, characterized the phenotypic profile of conditional knockdown mutants, and used *TgZnT* to rescue Zn^{2+} tolerance in a Zn^{2+} -intolerant *Saccharomyces cerevisiae* yeast mutant.

RESULTS

Identification of a Zn^{2+} transporter in *T. gondii*. With the aim of characterizing the potential role of the PLV in the survival and thriving of *Toxoplasma* during its extracellular passage, an essential phase of its lytic cycle, we looked at potential transporters that localize to the PLV and that could function in the transport of ions for which a strict control is required. One of these ions, Zn^{2+} , was especially interesting because of several reasons. First, Zn^{2+} levels need to be tightly controlled; second, there was proteomic evidence for the presence of a zinc transporter in *Toxoplasma* and in a PLV-enriched fraction (ToxoDB and unpublished data); and third, evidence for the proton gradient needed for its function was demonstrated in previous work (5). The Zn^{2+} transporter gene annotated in ToxoDB (TgGT1_251630) predicts the expression of a protein of 715 amino acids with a predicted molecular weight of 77 kDa and an isoelectric point of 5.86. We named the gene *TgZnT* because it is the single member of this family of Zn^{2+} transporters annotated in the *T. gondii* genome. The *TgZnT* gene product is predicted to contain 6 transmembrane domains (Fig. 1A), forming a structure similar to that of the *Escherichia coli* Zn^{2+} transporter YiiP (Fig. 1B).

We studied the phylogenetic profile of *TgZnT*, and for this we generated a bootstrapped neighbor-joining tree of aligned and trimmed sequences (see Fig. S1 in the supplemental material) of various ZnT family proteins from a variety of organisms as well as TgZnT and its apicomplexan orthologs (Fig. 1C). The tree analysis showed that TgZnT groups with the ZnT-2 family of plant and mammalian Zn^{2+} transporters (24) along with orthologs in other apicomplexan parasites (including both coccidian and




FIG 1 Sequence analysis of TgZnT. (A) Protter topology analysis of the TgZnT predicts for 6 transmembrane domains, which is typical of ZnT family transporters. Areas highlighted in yellow are regions used for polyclonal antibody production (Fig. 3). (B) Phyre2 modeling of TgZnT (red) shows a predicted structure similar to that of the *E. coli* ZnT transporter YiiP (gray). Side chains of the predicted Zn²⁺ binding residues in transmembrane helices II and V are shown in green. (C) Unrooted tree of TgZnT, apicomplexan orthologs, and other ZnTs. The branch to which TgZnT (red, bold) and its apicomplexan orthologs (red) belongs is the ZnT2-like subfamily, which primarily transports Zn²⁺. (D) Multiple-sequence alignment of transmembrane (TM) helices II and V of TgZnT and its apicomplexan orthologs with various other ZnTs that transport Zn²⁺. The histidines and aspartic acid residues that are predicted to be part of the intramembrane Zn²⁺-binding site (*) are conserved in TgZnT and its apicomplexan orthologs. Cp, *Cryptosporidium parvum*; Pf, *Plasmodium falciparum*; Et, *Eimeria tenella*; Nc, *Neospora caninum*; Os, *Oryza sativa*; At, *Arabidopsis thaliana*; Hs, *Homo sapiens*; Sh, *Stylosanthes hamata*; Mm, *Mus musculus*; Sc, *Saccharomyces cerevisiae*; Bs, *Bacillus subtilis*; Wm, *Wautersia metalldurans*; Ec, *Escherichia coli*.

hemsporidian parasites) (Fig. 1C). This grouping suggests that TgZnT and its orthologs may have derived from a single gene in a distant common ancestor of plants, mammals, and apicomplexans. TgZnT also possesses the histidine and aspartic acid residues thought to be required for intramembrane Zn²⁺ binding in transmembrane helices II and V (Fig. 1D).

TgZnT-HA localizes to the plant-like vacuole and to cytoplasmic vesicles. To investigate the localization of TgZnT, the TgGT1_251630 gene was endogenously tagged with a 3× hemagglutinin (3×HA) tag at its 3' end, using the ligation-independent cloning C-terminal tagging plasmid previously described (25). This approach avoids the overexpression and potential abnormal distribution of the tagged protein. Western blot analysis of a clonal parasite line expressing TgZnT-HA showed several bands around the predicted molecular weight of TgZnT plus the additional 4 kDa of the 3×HA tag (~82 kDa) (Fig. 2B). The presence of multiple bands suggests




FIG 2 C-terminal tagging of TgZnT and its localization to intracellular vesicles and the PLV. (A) Scheme showing the modified *TgZnT* locus (green), C-terminal HA tag (yellow), and selection marker (chloramphenicol acetyltransferase [CAT]; pink). (B) Western blot analysis of lysates obtained from tachyzoites of the *ku80* (parent) and *TgZnT-HA* clonal cell lines showing bands of the predicted molecular weight (82 kDa). Tubulin was used as a loading control. (C) Immunofluorescence assay (IFA) of an extracellular *TgZnT-HA* tachyzoite showing the partial colocalization of anti-HA (1:50; green) and anti-VP1 (1:2,000; red), a PLV marker. Labeling in the posterior compartment (arrow) was also observed. (D) IFA of intracellular *TgZnT-HA* tachyzoites showing labeling with anti-HA (1:50; TgZnT; green) and anti-VP1 (1:2,000; red). (E to I) Cryo-immuno electron microscopy (CryoIEM) of an extracellular tachyzoite using anti-HA antibodies shows that TgZnT-HA localizes to a posterior vacuole (Ei), small vesicles (F), large vesicles (G, I), and PLV structures (H, J) in extracellular tachyzoites. TgZnT-HA often localizes to invaginations of the PLV-like structures and larger vacuoles (arrows, Ei, H, and I), suggesting the potential fusion of TgZnT vesicles. CryoIEM was labeled with immunogold (10-nm beads). N, nucleus; R, rhoptry. Bars, 3 μ m (C and D), 500 nm (E and G to J), and 100 nm (F).

that TgZnT is posttranslationally modified, which is additionally supported by the prediction of phosphorylation and methylation sites annotated in the EuPathDB (26) entry for TgZnT (TgGT1_251630) (27, 28). Immunofluorescence analysis with a clonal parasite line expressing TgZnT-HA showed different distributions of the labeling in extracellular and intracellular tachyzoites (Fig. 2C and D). In extracellular tachyzoites, TgZnT-HA localized to two prominent vacuoles, one apical and one posterior. The apical vacuole showed partial colocalization with the vacuolar-H⁺-pyrophosphatase, a PLV marker (anti-VP1) (Fig. 2C). In intracellular tachyzoites, TgZnT-HA localized to dispersed vesicles throughout the cytoplasm which did not colocalize with the anti-VP1 labeling (Fig. 2D). We performed cryo-immuno electron microscopy (CryoIEM) of *TgZnT-HA* extracellular tachyzoites to obtain fine details of the TgZnT localization (Fig. 2E to J). Gold particle labeling was observed in structures ranging from small vesicles (~100 nm) (Fig. 2F) to large vacuoles (>250 nm) (Fig. 2E, G to J). Of particular note, we saw that labeling favored the invaginations into the larger vacuoles (Fig. 2Ei, H to J, arrows).

To investigate the localization of untagged, wild-type TgZnT, we generated specific antibodies against a fusion of two TgZnT loop domains (Fig. 1A, yellow) in mice. Western blot analysis of lysates from RH tachyzoites showed several bands around the




FIG 3 Localization of TgZnT with specific mouse antibodies and generation of conditional knockdown mutants. (A) IFA of an RH extracellular tachyzoite showing the partial colocalization of polyclonal mouse anti-TgZnT (α ZnT) with the PLV marker CRT-RFP. (B) IFA of intracellular tachyzoites showing anti-TgZnT labeling of vesicles throughout the tachyzoite, excluding the nucleus. There was no colocalization with the PLV marker CRT-RFP. (C) (i) Strategy for insertion of the tet7sag4 promoter (red arrow) into the *TgZnT* endogenous locus using CRISPR/Cas9. (ii) Final inducible knockdown locus (*i* Δ *znt*) showing the endogenous promoter (black arrow) and the 5' UTR (light green) displaced by the DHFR selection cassette (pink) and the tet7sag4 promoter (red) with the tetracycline (Tet) repressor (yellow), followed by the coding region of *TgZnT* with exons (green). (D) Western blot analysis of lysates from the parental strain (the Δ *ku80* *TATI* strain) and the Δ *znt* and *i* Δ *znt* mutants after growth with or without 0.5 μ g anhydrotetracycline (ATc). Lysate from *i* Δ *znt* tachyzoites after growth in ATc did not show labeling with anti-TgZnT. Tubulin was used as a loading control.

expected molecular weight of 77 kDa (Fig. 3D), similar to what was observed with TgZnT-HA (Fig. 2B). We also performed immunofluorescence assays (IFAs) using polyclonal anti-TgZnT, which showed the labeling of two large vacuoles in extracellular tachyzoites, and one of them showed colocalization with the red fluorescent protein (RFP)-tagged chloroquine resistance transporter (CRT), a PLV marker (Fig. 3A) (29). In intracellular tachyzoites we observed a dispersed vesicular localization (Fig. 3B) that

was also seen in the IFAs of TgZnT-HA tachyzoites. These vesicles did not colocalize with the vesicles labeled by CRT-RFP.

TgZnT knockout mutants exhibit reduced growth in the presence of extracellular Zn²⁺. To establish the role of TgZnT in the *T. gondii* lytic cycle, we first generated knockout mutants by inserting a dihydrofolate reductase (DHFR) resistance selection cassette at the beginning of exon 1 using the CRISPR/Cas9 system and a protospacer for this region of the gene (Fig. S2A). A Western blot analysis of lysates from a subclone (the Δznt clone) of the resulting mutants showed the absence of anti-TgZnT labeling, suggesting gene disruption (Fig. S2B). We complemented these mutants with a copy of *TgZnT* in an overexpression vector utilizing the tubulin promoter (pDTM3) (30). These clones (the Δznt -ZnT clones) overexpressed TgZnT, as was seen by Western blot analysis of their lysates (Fig. S2B). Immunofluorescence assays of parental strain RH and the knockout and complemented overexpressing mutants confirmed these results (Fig. S2C). The knockout mutants (the Δznt mutants) showed reduced growth in plaque assays (Fig. S2D), but the overexpression of TgZnT in the Δznt -ZnT clones was also deleterious for growth, and it was not possible to complement the growth phenotype of the Δznt mutant.

The effect of overexpression of *TgZnT* on parasite growth did not permit proper analysis of the specific biological functions of *TgZnT*, so we next created conditional mutants for *TgZnT*, which allowed for controlled expression of the gene. For this, we modified the endogenous *TgZnT* locus by inserting a tet7sag4 promoter at the 5' end of the predicted open reading frame (ORF). This element responds to anhydrotetracycline (ATc) by repressing expression of the downstream gene (Fig. 3C). Subclones (the final inducible knockdown locus [*i* Δznt] clones) were isolated, and Western blot analysis of lysates from these clonal lines revealed that expression was responsive to ATc (Fig. 3D).

We investigated the role of TgZnT in parasite growth, and we performed plaque assays in the presence ATc and in the absence of ATc (Fig. 4A). Plaques were significantly smaller when parasites were grown in the presence of ATc (+ATc mutants) (Fig. 4A and B). We next wanted to investigate if the mutants were less able to cope with high extracellular concentrations of Zn²⁺, and for this we first transfected mutant parasites with a red fluorescent protein and selected the cells by fluorescence-activated cell sorting. These cells allowed us to study growth by following the red fluorescence as a function of time (Fig. 4C and D). We grew parasites (with and without ATc) in the presence of several concentrations of extracellular Zn²⁺ (Fig. 4C and D) up to 100 μ M Zn²⁺, which did not show apparent toxicity to the host cells. Higher concentrations of Zn²⁺ were deleterious to the host cells (not shown). The growth results showed that the parental cell line grew fine at 1 to 10 μ M Zn²⁺ and that only a small decrease was observed at 25 μ M Zn²⁺. Higher concentrations of extracellular Zn²⁺ (75 to 100 μ M) were deleterious to the growth of the parental cells. The +ATc mutants were intolerant to higher concentrations of Zn²⁺ and showed a clear and significant growth difference at 1, 10, and 25 μ M Zn²⁺. At 75 μ M Zn²⁺, the +ATc mutants were significantly deficient in their tolerance to Zn²⁺. Interestingly, the zinc-dependent growth difference between the +ATc mutants and mutants grown in the absence of ATc (-ATc mutants) was ablated in media devoid of Zn²⁺ supplementation (containing only contaminating Zn²⁺). These results support our hypothesis that TgZnT plays a role in the extracellular Zn²⁺ tolerance of *T. gondii*.

TgZnT restores Zn²⁺ tolerance to Zn²⁺-sensitive yeast mutants. To investigate the Zn²⁺ transport function of TgZnT, we transformed *zrc1 Δ ::cot1 Δ* yeast mutants, which lack their vacuolar zinc transporters and are unable to grow in media containing high concentrations of Zn²⁺, with a pYES2 expression plasmid containing the cDNA for *TgZnT* under the control of the galactose promoter. Western blot analysis of lysates from these mutants grown in media containing galactose showed labeling with anti-TgZnT (Fig. 5A), with the mutants showing a similar multiple-band profile with bands with sizes comparable to the ones observed in *Toxoplasma* lysates (Fig. 3D). Plate




FIG 4 Knockdown of TgZnT results in reduced *in vitro* growth of *Toxoplasma*. (A) Representative plaque assay showing reduced plaque sizes of the *iΔznt* mutant grown in the presence of ATc (+ATc). (B) Quantification of plaque areas from three independent plaque assays ($n = 3$) showing that the reduced plaque size is significant. (C) Representative growth assay measuring the red fluorescence of parasites expressing tdTomato, showing that *iΔznt* mutants supplemented with ATc (red lines) have a growth defect that is exacerbated in the presence of higher extracellular ZnSO₄ concentrations. Controls without ATc are shown in blue. The concentration of ZnSO₄ added to the culture is indicated in each graph ($n = 3$). (D) Quantification of parasite numbers at 6 days postinfection showing that parental and mutant parasites grow at a similar rate in the absence of added ZnSO₄ (0 μM ZnSO₄) but that there is a significant reduction in the growth of parasites lacking TgZnT when ZnSO₄ is added to the medium ($n = 3$), *, $P > 0.05$; **, $P > 0.01$; ***, $P > 0.01$; n.s., not significant.

growth assays in the presence of different concentrations of ZnSO₄ revealed that *zrc1Δ::cot1Δ* mutants expressing TgZnT were capable of tolerating higher concentrations of Zn²⁺ (up to 300 μM), whereas the *zrc1Δ::cot1Δ* mutants transfected with an empty vector tolerated only 100 μM (Fig. 5B). Assays in liquid media showed that the *zrc1Δ::cot1Δ* mutants transfected with the empty vector pYES2 were unable to grow (Fig. 5C and D, red line) in the presence of 100 μM Zn²⁺, while the expression of TgZnT in the *zrc1Δ::cot1Δ* mutants led to a partial growth recovery (Fig. 5C and D, blue line).

DISCUSSION

We report that the gene *TgZnT*, present in the *T. gondii* genome, encodes the only annotated, functional Zn²⁺ transporter of the ZnT family in *T. gondii* and that this transporter is closely related to the ZnT2-like Zn²⁺ transporters found in plants. In extracellular tachyzoites, TgZnT localizes to large and small vesicles that, in electron microscopy images, were shown to fuse with large vacuoles, most likely the PLV. In intracellular tachyzoites, TgZnT localizes to vesicles that did not colocalize with either VP1 or *T. gondii* CRT. We hypothesize that these vesicles may be acidocalcisomes, which are similar to the zincosomes described in other cell types (19, 31). In this regard, there is evidence of the presence of large amounts of Zn²⁺ in acidocalcisomes of different species, as determined by X-ray microanalysis (32), and of Zn²⁺ transporters (ZnT) in acidocalcisomes of *Trypanosoma cruzi* (33) and *T. brucei* (34). Our laboratory previously determined the presence of Zn²⁺ in acidocalcisomes of *Toxoplasma* by X-ray microanalysis of whole cells (31, 35). It is likely that acidocalcisomes play a role in Zn²⁺




FIG 5 Expression of TgZnT restores Zn²⁺ tolerance to yeast. (A) Western blot analysis of lysates from parental and *zrc1Δ::cot1Δ* yeasts transformed with pYES2-TgZnT or pYES2 (empty vector) and grown in medium containing galactose for induction. Lysate from parental and *zrc1Δ::cot1Δ* yeasts transfected with pYES2-TgZnT shows labeling with anti-TgZnT. A portion of the Ponceau-stained membrane is shown as a loading control. (B) Representative example of agar plate growth assays (*n* = 3) showing that TgZnT expressing *zrc1Δ::cot1Δ::pYES2-TgZnT* mutants are capable of growth in medium supplemented with up to 300 μM ZnSO₄, in contrast to the *zrc1Δ::cot1Δ::pYES2* mutant, which can grow only in medium supplemented with up to 100 μM ZnSO₄. (C) Representative growth curves from 3 liquid culture assays show that *zrc1Δ::cot1Δ* mutants (blue) expressing TgZnT have increased tolerance to growth in medium supplemented with 100 μM ZnSO₄, in contrast to *zrc1Δ::cot1Δ* mutants not expressing TgZnT (red). The parental cell lines transformed with pYES2 and pYES2-TgZnT are shown as controls (yellow and green curves, respectively). (D) Quantification of growth assay endpoints (65 h) showing a significant difference in the increased growth of *zrc1Δ::cot1Δ* mutants when complemented with TgZnT (*n* = 3). *, *P* < 0.05; n.s., not significant; A.U., absorbance units.

transport and trafficking in *Toxoplasma*. Preliminary data by our group suggest that a zinc transporter of another family (the ZIP family) that typically transports zinc into the cytoplasm (in the opposite direction of ZnT family transporters) localizes to these vesicles as well, lending credence to this hypothesis.

The mechanism responsible for the delivery of Zn^{2+} to the PLV or other compartments, where it would be required for the activity of metalloenzymes and other metalloproteins, has not been characterized in *T. gondii* or any other organism. It is possible that TgZnT distributes Zn^{2+} to various compartments as a way of activating apo-metalloenzymes, which are inactive in low- Zn^{2+} compartments. The distribution of Zn^{2+} to these compartments could be a mechanism for regulating the activity of these enzymes. There are numerous metalloproteases in *T. gondii* that are predicted to require Zn^{2+} as a cofactor for their activity (36–39), and due to the promiscuous activity of metalloproteases, they would require tight control in order to prevent unintended proteolytic activity. The presence or absence of the required Zn^{2+} cofactor would provide for potential regulation of their activity. The fusion of TgZnT vesicles or acidocalcisomes to the PLV in extracellular tachyzoites would also fit this model, as the PLV shares characteristics of a lysosome and proteolytic activity could be activated by the fusion of vesicles carrying Zn^{2+} and TgZnT at their membrane. The phosphorylation sites annotated in TgZnT may play a role in the regulation of transport activity, as was described for the human ZIP7 transporter (40).

In extracellular tachyzoites, our results support the hypothesis that TgZnT plays a role in the tolerance of *T. gondii* to the shift to high Zn^{2+} concentration upon egress. Our finding that the growth phenotype of the $\Delta TgZnT$ mutants was eliminated upon removal of supplementary Zn^{2+} from the media is the most significant support for this proposed role. The ability of TgZnT to restore Zn^{2+} tolerance when heterologously expressed in yeast mutants also provides support for its Zn^{2+} -transporting function. Prior to egress, the dispersed nature of TgZnT vesicles in intracellular tachyzoites may allow for the rapid sequestration of Zn^{2+} throughout the tachyzoite upon egress and a subsequent trafficking of the vesicles to the PLV for final sequestration.

In summary, this report describes a functional Zn^{2+} transporter in *T. gondii* capable of rescuing Zn^{2+} tolerance upon heterologous expression in yeast mutants. TgZnT localizes to vesicles that fuse with the PLV, and its absence in *T. gondii* tachyzoites causes a Zn^{2+} concentration-dependent growth defect that becomes more pronounced with high concentrations of extracellular Zn^{2+} . TgZnT is the first Zn^{2+} transporter to be characterized in an apicomplexan parasite, and its existence as the sole member of this family of Zn^{2+} transporters in these organisms suggests that its role may be conserved throughout the phylum.

MATERIALS AND METHODS

Gene identification and phylogenetic analysis. A gene (TgGT1_251630, UniProt accession number [SVVOD3](#)) annotated as a member of the solute carrier 30 family and an ortholog of ZnT-2 (UniProt accession number [Q9BRI3](#)) was cloned and sequenced. The ORF of the annotated gene in the current version of ToxoDB encodes a protein of 896 amino acids with a predicted molecular weight of 97 kDa; however, we determined through sequencing and experimental evidence that the translation initiation site annotated in a previous version of ToxoDB (TGME49_chrXII:5,501,102) was the correct one.

Generation of mutants. For C-terminal tagging of the TgZnT gene, the 3' 1,662 bp (minus the stop codon) of the gene annotated as a member of the solute carrier 30a2 family (slc30a2), TgGT1_251630, was amplified using primers P1 and P2 (see Table S2 in the supplemental material), which added the sequence required for ligation-independent cloning. The PCR product was purified using a Qiaex II gel extraction kit (Qiagen) and cloned into the pLIC-3×HA-CAT plasmid. The purified PCR product and plasmid were treated and combined as described by Huynh and Caruthers (25). Fifty micrograms of the sterilized plasmid pTgZnT-3×HA-CAT was transfected into 1×10^7 RH $\Delta ku80$ *TATI* parasites (41). Transfected parasites were selected with 20 μ M chloramphenicol, and clones were isolated by limiting dilution. The genomic DNA of the clones was isolated and screened by PCR using a primer upstream of the original amplification from *TgZnT* (forward primer P3) and downstream pLIC-3×HA-CAT reverse primer P4 (Table S2). Clones were further confirmed by Western blot analysis.

Disruption of the *TgZnT* gene in RH was achieved by transfecting tachyzoites with 1 μ g of pSAG1::CAS9-U6::sgUPRT (catalog number 54467; Addgene) (42), with the protospacer region being replaced with a protospacer (AGGAAGGCGTTTCCCCGTC) near the 5' end of the *TgZnT* coding region (modified with a New England Biolabs QuikChange site-directed mutagenesis kit by using primers P5 and P6) along with a separate dihydrofolate reductase (DHFR) drug selection cassette product generated via PCR. The parasites were selected with pyrimethamine followed by subcloning. Complementation/overexpression of *TgZnT* was accomplished by cloning the *TgZnT* gene, including the untranslated regions (UTRs) and potential promoter region, into the pCTH3 plasmid. The construct was transfected into Δznt tachyzoites and selected using chloramphenicol, followed by subcloning.

For conditional knockdown of TgZnT, primers P13 and P14 were used to introduce the protospacer CGCGTCTTCAGCTCTCGCCT into pSAG1::CAS9-U6::sgUPRT, which then became pSAG1::CAS9-U6::sgZnT. Homology regions corresponding to the region upstream of the protospacer (TTGCTCTTTCGCTTCTCTGCTCTGCGTTTCGCTG) and the region at the beginning with the translational start codon (GCGGCTTGGCTGCGCCGCCGCTTCTTGAACGCGGCAT) were added to a base primer (primers P15 and P16) to amplify the promoter insertion cassette (43). Four micrograms of linearized PCR product and 1 μ g of pSAG1::CAS9-U6::sgZnT were transfected into RH $\Delta ku80$ TATI parasites. Pyrimethamine (10 μ M) was added to the transfection reaction mixture 24 h later, and the population was subcloned. Anhydrotetracycline (0.5 μ g) was added to knock down the expression of ZnT.

Parasite cultures and generation of mutants. Tachyzoites of the *T. gondii* RH (25) and RH $\Delta ku80$ TATI (43) strains were cultured in human telomerase reverse transcriptase (hTert) fibroblasts in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% fetal bovine serum, 1 mM sodium pyruvate, and 2 mM glutamine. Tachyzoites were obtained from infected hTert cells by passing them through a 25-gauge needle or otherwise collected from the supernatant of infected cells after natural egress. The RH $\Delta ku80$ TATI strain was obtained from Boris Striepen (University of Georgia).

Plaque and growth assays. Plaque assays were performed as previously described (30) with modifications. For plaque growth assays, 125 tachyzoites were used for infection of hTert fibroblasts and allowed to grow for 10 days prior to fixing and staining. Growth assays of fluorescent cells were performed using TdTomato-expressing parasites in 96-well plates preseeded with hTert fibroblasts. Serum-free DMEM without phenol red was used for the growth assay, and ZnSO₄ and ATc were added, when appropriate, along with 4,000 tachyzoites per well. The fluorescence (594 nm) from each well was recorded every 24 h for 8 days using a SpectraMax E² plate spectrometer. A standard curve to determine parasite numbers was generated on the day of inoculation using known numbers of TdTomato-expressing parasites.

TgZnT loop fusion expression and antibody production. TgZnT-LF was constructed by cloning two loops (Fig. 1A) of the TgZnT cDNA using overlapping regions. The primers used were P9 and P10 for the first part of the fusion construct and P11 and P12 for the second part. The fusion protein was cloned into the PQE80L expression vector and transformed into *E. coli*. After induction with 1 mM IPTG (isopropyl- β -D-thiogalactopyranoside), soluble recombinant TgZnTLF was purified using a 1-ml HisPur nickel-affinity column (Thermo Fisher).

Antibodies against the recombinant TgZnT loop fusion protein (rTgZnT-LF) were generated in mice. Six CD-1 mice (Charles River) were inoculated intraperitoneally with 100 μ g of rTgZnT-LF mixed with complete Freund adjuvant, followed by two boosts with 50 μ g of rTgZnT-LF, with each boost being mixed with incomplete Freund adjuvant. The final serum was collected by cardiac puncture after CO₂ euthanasia. The animal protocol used was approved by the UGA Institutional Animal Care and Use Committee (IACUC).

Western blot analysis and immunofluorescence assays. Purified tachyzoites were treated with cell lysis buffer M (Sigma) and 25 units of Benzonase (Novagen) for 5 min at room temperature, followed by addition of an equal volume of 2% SDS–1 mM EDTA solution. Total protein was quantified with a NanoDrop spectrophotometer (Thermo Scientific). Samples were resolved using a 10% bisacrylamide gel in a Tris-HCl–SDS buffer system (Bio-Rad). Gels were transferred for Western blot analysis. Primary antibody dilutions were as follows: 1:100 for anti-HA (monoclonal rat; Roche) and 1:1,000 for mouse anti-TgZnT. Secondary horseradish peroxidase-labeled antibodies were used at 1:10,000 dilutions.

Indirect immunofluorescence assays (IFA) were performed on either naturally egressed tachyzoites or infected hTert monolayers. Parasites or monolayers were washed once using buffer A with glucose (BAG; 116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO₄, 50 mM HEPES, pH 7.2, 5.5 mM glucose) and then fixed with 3% formaldehyde for 15 min, followed by permeabilization using 0.25% Triton X-100 for 10 min and blocking with 3% bovine serum albumin. Labeling was performed as previously described (5). Images were collected using an Olympus IX-71 inverted fluorescence microscope with a Photometric CoolSnapHQ charge-coupled-device camera driven by DeltaVision software (Applied Precision, Seattle, WA). Super-resolution images were collected using an Elyra S1 superresolution structured illumination microscopy system (Zeiss). The dilutions used were 1:2,000 for rabbit anti-VP1, 1:1,000 for anti-TgZnT, and 1:50 for rat anti-HA (Roche).

Immunoelectron microscopy. Extracellular *T. gondii* parasites endogenously expressing the C-terminal 3 \times HA tag (TgZnT-HA) were washed twice with phosphate-buffered saline (PBS) before fixation in 4% paraformaldehyde (Electron Microscopy Sciences, PA) in 0.25 M HEPES (pH 7.4) for 1 h at room temperature and then in 8% paraformaldehyde in the same buffer overnight at 4°C. Parasites were pelleted in 10% fish skin gelatin, and the gelatin-embedded pellets were infiltrated overnight with 2.3 M sucrose at 4°C and frozen in liquid nitrogen. Ultrathin cryosections were incubated in PBS and 1% fish skin gelatin containing mouse anti-HA antibody at a 1/5 dilution and then exposed to the secondary antibody, which was revealed with 10-nm protein–anti-gold conjugates. Sections were observed, and images were recorded with a Philips CM120 electron microscope (Eindhoven, the Netherlands) under 80 kV.

Yeast zinc tolerance assays. Parental and zinc-intolerant *zrc1* Δ ::*cot1* Δ mutants (44) of *Saccharomyces cerevisiae* were transformed with the pYES2 empty vector or pYES2-TgZnT. Western blot analyses using mouse anti-TgZnT (1:1,000) were used to confirm expression in the pYES2-TgZnT-transformed cells. Yeast plate growth assays were performed on 1.5% agar plates containing a pH 6.5 complete supplement mixture lacking uracil (CSM–Ura; Sunrise Science) supplemented with 2% galactose and adjusted to various concentrations of Zn²⁺ using ZnSO₄. Assays were performed using 3 \times 10⁵ yeast cells per 10- μ l droplet and imaged after 48 h of growth.

Liquid growth assays were performed as described by Stasic et al. (8) with modifications. Yeast cells were grown on 96-well plates in CSM–Ura with 2% galactose that was either supplemented with 100 μ M ZnSO₄ or not supplemented. Each well was inoculated with 6×10^6 yeast cells in 200 μ l. Readings were performed every hour using a BioTek Synergy H1 hybrid tester.

Statistical analyses, modeling, alignments, and tree generation. All statistical analyses were performed using GraphPad Prism software (version 7). Modeling was performed using the Phyre2 server (45). Alignments were performed using the T-Coffee multiple-sequence alignment server (46) and manually trimmed to remove gaps. Trees were generated using the software Geneious and the Juke-Cantor algorithm and bootstrapped (100 cycles) to generate the consensus tree.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mSphere.00086-19>.

FIG S1, TIF file, 2.8 MB.

FIG S2, PDF file, 0.8 MB.

TABLE S1, PDF file, 0.1 MB.

TABLE S2, PDF file, 0.05 MB.

ACKNOWLEDGMENTS

We thank Boris Striepen, Vern Carruthers, and David Bzik for host cells and plasmids. We thank Melissa Storey for her help in the generation of the antibodies against TgZnT. We thank the Biomedical Microscopy Core, Coverdell Center, for the use of their microscopes and Muthugapatti K. Kandasamy for training on their use. We thank David Eide for graciously providing the yeast strains for this study.

Funding for this work was provided by the U.S. National Institutes of Health (grants AI-128356 and AI-096836 to S.N.J.M. and AI060767 to I.C.). N.M.C. was supported by a predoctoral fellowship from the American Heart Association (16PRE27390008). A.J.S. was partially supported by an OVPR graduate fellowship and a T32 Training in Tropical and Emerging Global Diseases grant (AI060546).

REFERENCES

- Holland GN. 2004. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. *Am J Ophthalmol* 137:1–17.
- Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS. 1984. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. *JAMA* 252:913–917. <https://doi.org/10.1001/jama.1984.03350070031018>.
- Wong SY, Remington JS. 1994. Toxoplasmosis in pregnancy. *Clin Infect Dis* 18:853–861. <https://doi.org/10.1093/clinids/18.6.853>.
- Blader IJ, Coleman BI, Chen CT, Gubbels MJ. 2015. Lytic cycle of *Toxoplasma gondii*: 15 years later. *Annu Rev Microbiol* 69:463–485. <https://doi.org/10.1146/annurev-micro-091014-104100>.
- Miranda K, Pace DA, Cintron R, Rodrigues JCF, Fang J, Smith A, Rohloff P, Coelho E, de Haas F, de Souza W, Coppens I, Sibley LD, Moreno SNJ. 2010. Characterization of a novel organelle in *Toxoplasma gondii* with similar composition and function to the plant vacuole. *Mol Microbiol* 76:1358–1375. <https://doi.org/10.1111/j.1365-2958.2010.07165.x>.
- Parussini F, Coppens I, Shah PP, Diamond SL, Carruthers VB. 2010. Cathepsin L occupies a vacuolar compartment and is a protein maturase within the endo/exocytic system of *Toxoplasma gondii*. *Mol Microbiol* 76:1340–1357. <https://doi.org/10.1111/j.1365-2958.2010.07181.x>.
- Liu J, Pace D, Dou Z, King TP, Guidot D, Li ZH, Carruthers VB, Moreno SN. 2014. A vacuolar-H(+)-pyrophosphatase (TgVP1) is required for microneme secretion, host cell invasion, and extracellular survival of *Toxoplasma gondii*. *Mol Microbiol* 93:698–712. <https://doi.org/10.1111/mmi.12685>.
- Stasic AJ, Chasen NM, Dykes EJ, Vella SA, Asady B, Starai VJ, Moreno SNJ. The *Toxoplasma* vacuolar H⁺-ATPase regulates intracellular pH and impacts the maturation of essential secretory proteins. *Cell Rep*, in press.
- Sheline CT, Behrens MM, Choi DW. 2000. Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. *J Neurosci* 20:3139–3146. <https://doi.org/10.1523/JNEUROSCI.20-09-03139.2000>.
- Choi DW, Koh JY. 1998. Zinc and brain injury. *Annu Rev Neurosci* 21:347–375. <https://doi.org/10.1146/annurev.neuro.21.1.347>.
- Kim AH, Sheline CT, Tian M, Higashi T, McMahon RJ, Cousins RJ, Choi DW. 2000. L-type Ca(2+) channel-mediated Zn(2+) toxicity and modulation by ZnT-1 in PC12 cells. *Brain Res* 886:99–107. [https://doi.org/10.1016/S0006-8993\(00\)02944-9](https://doi.org/10.1016/S0006-8993(00)02944-9).
- Maret W. 2009. Molecular aspects of human cellular zinc homeostasis: redox control of zinc potentials and zinc signals. *Biomaterials* 22:149–157. <https://doi.org/10.1007/s10534-008-9186-z>.
- Yamasaki S, Sakata-Sogawa K, Hasegawa A, Suzuki T, Kabu K, Sato E, Kurosaki T, Yamashita S, Tokunaga M, Nishida K, Hirano T. 2007. Zinc is a novel intracellular second messenger. *J Cell Biol* 177:637–645. <https://doi.org/10.1083/jcb.200702081>.
- Coleman JE. 1992. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. *Annu Rev Biochem* 61:897–946. <https://doi.org/10.1146/annurev.bi.61.070192.004341>.
- Andreini C, Banci L, Bertini I, Rosato A. 2006. Counting the zinc-proteins encoded in the human genome. *J Proteome Res* 5:196–201. <https://doi.org/10.1021/pr050361j>.
- Maret W. 2013. Zinc biochemistry: from a single zinc enzyme to a key element of life. *Adv Nutr* 4:82–91. <https://doi.org/10.3945/an.112.003038>.
- Maret W. 2005. Zinc coordination environments in proteins determine zinc functions. *J Trace Elem Med Biol* 19:7–12. <https://doi.org/10.1016/j.jtemb.2005.02.003>.
- Outten CE, O'Halloran TV. 2001. Femtomolar sensitivity of metalloregulatory proteins controlling zinc homeostasis. *Science* 292:2488–2492. <https://doi.org/10.1126/science.1060331>.
- Ballestin R, Molowny A, Marin MP, Esteban-Pretel G, Romero AM, Lopez-Garcia C, Renau-Piqueras J, Ponsoda X. 2011. Ethanol reduces zincosome formation in cultured astrocytes. *Alcohol Alcohol* 46:17–25. <https://doi.org/10.1093/alcac/agq079>.
- Woodier J, Rainbow RD, Stewart AJ, Pitt SJ. 2015. Intracellular zinc modulates cardiac ryanodine receptor-mediated calcium release. *J Biol Chem* 290:17599–17610. <https://doi.org/10.1074/jbc.M115.661280>.
- Bird AJ, McCall K, Kramer M, Blankman E, Winge DR, Eide DJ. 2003. Zinc

- fingers can act as Zn²⁺ sensors to regulate transcriptional activation domain function. *EMBO J* 22:5137–5146. <https://doi.org/10.1093/emboj/cdg484>.
22. Michael SF, Kilfoil VJ, Schmidt MH, Amann BT, Berg JM. 1992. Metal binding and folding properties of a minimalist Cys2His2 zinc finger peptide. *Proc Natl Acad Sci U S A* 89:4796–4800. <https://doi.org/10.1073/pnas.89.11.4796>.
 23. Frederickson CJ, Giblin LJ, Krężel A, McAdoo DJ, Muelle RN, Zeng Y, Balaji RV, Masalha R, Thompson RB, Fierke CA, Sarvey JM, de Valdenbro M, Prough DS, Zornow MH. 2006. Concentrations of extracellular free zinc (pZn)_e in the central nervous system during simple anesthetization, ischemia and reperfusion. *Exp Neurol* 198:285–293. <https://doi.org/10.1016/j.expneurol.2005.08.030>.
 24. Montanini B, Blaudez D, Jeandroz S, Sanders D, Chalot M. 2007. Phylogenetic and functional analysis of the cation diffusion facilitator (CDF) family: improved signature and prediction of substrate specificity. *BMC Genomics* 8:107. <https://doi.org/10.1186/1471-2164-8-107>.
 25. Huynh MH, Carruthers VB. 2009. Tagging of endogenous genes in a *Toxoplasma gondii* strain lacking Ku80. *Eukaryot Cell* 8:530–539. <https://doi.org/10.1128/EC.00358-08>.
 26. Warrenfeltz S, Basenko EY, Crouch K, Harb OS, Kissinger JC, Roos DS, Shanmugasundram A, Silva-Franco F. 2018. EuPathDB: The Eukaryotic Pathogen Genomics Database Resource. *Methods Mol Biol* 1757:69–113. https://doi.org/10.1007/978-1-4939-7737-6_5.
 27. Trecek M, Sanders JL, Elias JE, Boothroyd JC. 2011. The phosphoproteomes of *Plasmodium falciparum* and *Toxoplasma gondii* reveal unusual adaptations within and beyond the parasites' boundaries. *Cell Host Microbe* 10:410–419. <https://doi.org/10.1016/j.chom.2011.09.004>.
 28. Yakubu RR, Silmon de Monerri NC, Nieves E, Kim K, Weiss LM. 2017. Comparative monomethylarginine proteomics suggests that protein arginine methyltransferase 1 (PRMT1) is a significant contributor to arginine monomethylation in *Toxoplasma gondii*. *Mol Cell Proteomics* 16: 567–580. <https://doi.org/10.1074/mcp.M117.066951>.
 29. Warring SD, Dou Z, Carruthers VB, McFadden GI, van Dooren GG. 2014. Characterization of the chloroquine resistance transporter homologue in *Toxoplasma gondii*. *Eukaryot Cell* 13:1360–1370. <https://doi.org/10.1128/EC.00027-14>.
 30. Chasen NM, Asady B, Lemgruber L, Vommaro RC, Kissinger JC, Coppens I, Moreno S. 2017. A glycosylphosphatidylinositol-anchored carbonic anhydrase-related protein of *Toxoplasma gondii* is important for rhoptry biogenesis and virulence. *mSphere* 2:e00027-17. <https://doi.org/10.1128/mSphere.00027-17>.
 31. Rohloff P, Miranda K, Rodrigues JC, Fang J, Galizzi M, Plattner H, Hentschel J, Moreno SN. 2011. Calcium uptake and proton transport by acidocalcisomes of *Toxoplasma gondii*. *PLoS One* 6:e18390. <https://doi.org/10.1371/journal.pone.0018390>.
 32. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. 2005. Acidocalcisomes—conserved from bacteria to man. *Nat Rev Microbiol* 3:251–261. <https://doi.org/10.1038/nrmicro1097>.
 33. Ferella M, Nilsson D, Darban H, Rodrigues C, Bontempi EJ, Docampo R, Andersson B. 2008. Proteomics in *Trypanosoma cruzi*—localization of novel proteins to various organelles. *Proteomics* 8:2735–2749. <https://doi.org/10.1002/pmic.200700940>.
 34. Huang G, Ulrich PN, Storey M, Johnson D, Tischer J, Tovar JA, Moreno SN, Orlando R, Docampo R. 2014. Proteomic analysis of the acidocalcisome, an organelle conserved from bacteria to human cells. *PLoS Pathog* 10:e1004555. <https://doi.org/10.1371/journal.ppat.1004555>.
 35. Luo S, Vieira M, Graves J, Zhong L, Moreno SN. 2001. A plasma membrane-type Ca(2+)-ATPase co-localizes with a vacuolar H(+)-pyrophosphatase to acidocalcisomes of *Toxoplasma gondii*. *EMBO J* 20:55–64. <https://doi.org/10.1093/emboj/20.1.55>.
 36. Hajagos BE, Turetzky JM, Peng ED, Cheng SJ, Ryan CM, Souda P, Whitelegge JP, Lebrun M, Dubremetz JF, Bradley PJ. 2012. Molecular dissection of novel trafficking and processing of the *Toxoplasma gondii* rhoptry metalloprotease toxolysin-1. *Traffic* 13:292–304. <https://doi.org/10.1111/j.1600-0854.2011.01308.x>.
 37. Laliberté J, Carruthers VB. 2011. *Toxoplasma gondii* toxolysin 4 is an extensively processed putative metalloproteinase secreted from micronemes. *Mol Biochem Parasitol* 177:49–56. <https://doi.org/10.1016/j.molbiopara.2011.01.009>.
 38. Palacios M, Hajagos BE, Bradley PJ. 2007. The role of the insulinase-like protein toxolysin-2 in host cell infection by *Toxoplasma gondii*, abstr E15-FRI. Abstr 2007 SACNAS Natl Conf, Kansas City, MO, 11 to 14 October 2007. https://static.aminer.org/pdf/PDF/000/291/363/deformable_templates_for_recognizing_the_shape_of_the_zebra_fish.pdf.
 39. Hajagos BE. 2011. *Toxoplasma gondii* employs secreted metalloproteases for host cell invasion and intracellular survival. ProQuest Dissertations & Theses A&I 963700042. University of California, Los Angeles, Los Angeles, CA.
 40. Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P. 2012. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. *Sci Signal* 5:ra11. <https://doi.org/10.1126/scisignal.2002585>.
 41. Soldati D, Boothroyd JC. 1993. Transient transfection and expression in the obligate intracellular parasite *Toxoplasma gondii*. *Science* 260: 349–352. <https://doi.org/10.1126/science.8469986>.
 42. Shen B, Brown KM, Lee TD, Sibley LD. 2014. Efficient gene disruption in diverse strains of *Toxoplasma gondii* using CRISPR/CAS9. *mBio* 5:e01114-14. <https://doi.org/10.1128/mBio.01114-14>.
 43. Sheiner L, Demerly JL, Poulsen N, Beatty WL, Lucas O, Behnke MS, White MW, Striepen B. 2011. A systematic screen to discover and analyze apicoplast proteins identifies a conserved and essential protein import factor. *PLoS Pathog* 7:e1002392. <https://doi.org/10.1371/journal.ppat.1002392>.
 44. MacDiarmid CW, Milanick MA, Eide DJ. 2003. Induction of the ZRC1 metal tolerance gene in zinc-limited yeast confers resistance to zinc shock. *J Biol Chem* 278:15065–15072. <https://doi.org/10.1074/jbc.M300568200>.
 45. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. *Nat Protoc* 10:845–858. <https://doi.org/10.1038/nprot.2015.053>.
 46. Notredame C, Higgins DG, Heringa J. 2000. T-Coffee: a novel method for fast and accurate multiple sequence alignment. *J Mol Biol* 302:205–217. <https://doi.org/10.1006/jmbi.2000.4042>.